Fusion of P3 X 63 Ag8 mouse myeloma cells with splenocytes obtained from mice immunized with cells derived from human colorectal carcinomas resulted in the production of antibody-secreting hybridomas. Two hybridomas (1083-17 and 1116-56) and their clones secreted antibodies binding specifically to human colorectal carcinoma cells either grown in culture or obtained from patients, but did not bind to normal colonic mucosa or other normal and malignant human cells. The binding specificity was consistent in three assays: radioimmunoassay, mixed hemadsorption, and immunofluorescence. Adsorption of these antibodies to colorectal carcinoma cell lines totally eliminated their specific binding.
Despite a large number of reports, there is no evidence available that tumor-specific antigens are present on cells of human colorectal carcinoma (1, 2) . For instance, the carcinoembryonic antigen(s) present on colorectal carcinoma are also expressed by other human tumors and by normal tissues (1) . In chemically induced colon carcinomas of the rat, on the other hand, there is evidence of common tumor-specific antigens (3) (4) (5) . - In a previous publication (6) , we reported the presence on human melanoma cells of tumor-specific antigens detected by monoclonal antibodies. The present paper extends these observations to antigen(s) expressed by human colorectal carci Leibovitz (7, 8) . Other human cell lines included myeloma Sed (9) , lymphoid line P3 HR-1 (10) , and fibrosarcoma HT 1080, the last of which was obtained from C. M. Croce. Melanoma cell lines WM8 and WM9 and astrocytoma cell line ASTRO (3) MsBa (tumor obtained from J. T. Robertson, University of Tennessee Medical School, Memphis, TN) were established in our laboratory. Normal human cell lines were fetal fibroblasts Flow 4000 (kidney) and MRC-5 (lung) from Flow Laboratories (Rockville, MD) and WI38, Hff, and normal skin fibroblasts (6) .
Human Cells Freshly Isolated from Patients. Histologically documented colorectal carcinomas with adjacent normal colonic mucosa were obtained during surgery for the treatment of patients (from E. Catalano, Hahnemann School of Medicine, Philadelphia, PA). Portions of tumor and normal colon tissue were extensively washed in Eagle's minimal essential medium. The samples were then freed of connective tissue and remaining necrotic areas and were processed as follows: Separate specimens of tumor and normal intestinal mucosa distal to the tumor were finely minced and washed vigorously with four changes of medium. After removal of all debris, small fragments of tissue were forced through a stainless steel mesh and resuspended in medium. The single cell suspension was then purified according to the method of Vose et al. (11) . Briefly, the cell suspension was sedimented by centrifugation at 200 X g for 5 min and then purified on a discontinuous Ficoll/Isopaque gradient (50, 75, and 100%). The interphases and the bottom fraction were collected. The viability of purified cells, measured by dye exclusion, was in excess of 90%. The cells were washed with medium, adjusted to 1 X 107 cells/ml in radioimmunoassay (RIA) buffer (6) , and used for testing.
Immune Spleen Cells. Five colorectal carcinoma cell lines were used for the immunization of mice (Table 1) . BALB/c mice were immunized for a secondary response as described (6) . For a primary response, BALB/c mice received a single intravenous injection of 1-2 X 106 colorectal carcinoma cells. Immunized mice were sacrificed 5-6 days later, and a spleen cell suspension was prepared as described (12) .
Production of Hybridomas. The fusion of immune splenocytes with mouse myeloma P3 X 63 Ag8 cells was performed as described (12 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 76 (1979) 1439 (Table 4 ). In contrast, none of the cells of human tumors other than colorectal carcinoma and none of the normal human cells (Table 4) in the RIA (expressed in cpm) may, as in the case of antimelanoma antibodies, reflect different affinities for the antigenic determinants, variations in the total number of determinants on the target cells, or differences in the distribution of the determinants. The presence of identical or crossreactive epitopes seems to be evident in all but one of nine tumor cell lines as determined by RIA. This was confirmed in two other assays (Table 3 ) and by the fact that absorption of the monoclonal antibodies by four different colorectal carcinomas totally eliminated the specific binding of ACRC antibodies (Table   4 ). 
